

Iowa Department of Human Services

Iowa Health Link Hawki

Request for Prior Authorization BIOLOGICALS FOR INFLAMMATORY BOWEL DISEASE

FAX Completed Form To 1 (877) 733-3195 Provider Help Desk 1 (844) 236-1464

(PLEASE PRINT - ACCURACY IS IMPORTANT)

	•		-	` ,	
IA Medicaid Member ID #	Patient name			DOB	
Patient address					
Provider NPI	Prescriber nam	e		Phone	
Prescriber address				Fax	
Pharmacy name	Address			Phone	
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.					
Pharmacy NPI	Pharmacy fax	, ,	NDC		
only for cases in which there is documentation of a previous trial and therapy failure with a preferred agent. Payment will be considered under the following conditions: 1) Patient has been screened for hepatitis B and C, patients with active hepatitis B will not be considered for coverage; and 2) Patient has been screened for latent TB infection, patients with latent TB will only be considered after one month of TB treatment and patients with active TB will only be considered upon completion of TB treatment. In addition to the above: Requests for TNF Inhibitors: 1) Patient has not been treated for solid malignancies, nonmelanoma skin cancer, or lymphoproliferative malignancy within the last 5 years of starting or resuming treatment with a biological agent; and 2) Patient does not have a diagnosis of congestive heart failure (CHF) that is New York Heart Association (NYHA) class Ill or IV and with an ejection fraction of 50% or less. Requests for Interleukins: Medication will not be given concurrently with live vaccines. The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.					
Preferred ☐ Humira ☐ Humira Starter Kit		Non-Preferred ☐ Cimzia (prefilled ☐ Simponi	syringe)	☐ Skyrizi ☐ Stelara	
Strength Dosage Instruct	ions	Quantity	Days Su	— apply	
Screening for Hepatitis B: Date:				□ No	
Screening for Hepatitis C: Date:					
Screening for Latent TB infection: Date:		Results:			
Requests for TNF Inhibitors:					
Has patient received treatmen lymphoproliferative malignant agent? Yes No	cy within last 5 ye				biologic
Does patient have a diagnosis less? ☐ Yes ☐ No	of NYHA class I	ll or IV CHF diagnos	sis with eje	ction fraction o	of 50% or

Requests for Interleukins:

Request for Prior Authorization BIOLOGICALS FOR INFLAMMATORY BOWEL DISEASE

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Will medication be given concurrently with live vaccines?	s No				
☐ Crohn's Disease – Payment will be considered following an inadequate response to two preferred conventional therapies including aminosalicylates (mesalamine, sulfasalazine), azathioprine/6-mercaptopurine, and/or methotrexate.					
Trial Drug Name/Dose:	Гrial dates:				
Reason for failure:					
Trial Drug Name/Dose:	Trial dates:				
Reason for failure:					
Reason for use of Non-Preferred drug requiring prior approval:					
response to two preferred conventional therapies including aminomercaptopurine. Trial Drug Name/Dose:	•				
Reason for failure:					
Trial Drug Name/Dose:	_Trial dates:				
Reason for failure:					
Reason for use of Non-Preferred drug requiring prior approval:					
Possible drug interactions/conflicting drug therapies/other medical cond	itions to consider:				
Attach lab results and other documentation as necessary.					
Prescriber signature (Must match prescriber listed above.)	Date of submission				

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.

PAA-1020 Page 2 of 2